<DOC>
	<DOC>NCT01276223</DOC>
	<brief_summary>The purpose of this study was to determine if difluprednate ophthalmic emulsion is effective in reducing the ocular symptoms of dry eye disease, as measured by a global Visual Analog Scale (VAS) discomfort score.</brief_summary>
	<brief_title>Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients</brief_title>
	<detailed_description>Following Run-In, patients qualifying for treatment were randomized 1:1 to receive Durezol (experimental group) or Vehicle (control group) for 5 weeks.</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Fluprednisolone</mesh_term>
	<mesh_term>Difluprednate</mesh_term>
	<criteria>Normal subjects: No known history of dry eye disease. Noncontact lens wearer. No current use of artificial tears or any other dry eye treatment. OR Dry eye patients: At least a 6 month history of dry eye. Noncontact lens wearer. Uses artificial tears. Experiences persistent ocular discomfort. Other protocoldefined inclusion criteria may apply. The presence of any acute infectious or noninfectious ocular conditions in either eye within 1 month of Visit 1. Severe Sjogren's Syndrome. Lid function abnormalities. Use of steroids, tetracycline, doxycycline, etc., within 30 days of Visit 1. History of corneal surgery including refractive surgeries. History of glaucoma or ocular hypertension Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Dry eye</keyword>
	<keyword>ocular discomfort</keyword>
</DOC>